These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25475380)

  • 1. Radionuclide therapy for osseous metastases in prostate cancer.
    Abi-Ghanem AS; McGrath MA; Jacene HA
    Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
    Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
    Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
    Cheetham PJ; Petrylak DP
    Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
    Bruland ØS; Nilsson S; Fisher DR; Larsen RH
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
    Nilsson S
    Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
    Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
    Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
    Lewis B; Chalhoub E; Chalouhy C; Sartor O
    Oncology (Williston Park); 2015 Jul; 29(7):483-8. PubMed ID: 26178336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.
    Patel CM; Wadas TJ; Shiozawa Y
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 dichloride for the treatment of metastatic prostate cancer.
    Turner PG; O'Sullivan J
    Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 for the treatment of prostate cancer.
    Hafeez S; Parker C
    Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
    Pandit-Taskar N; Larson SM; Carrasquillo JA
    J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Palliative treatment of bone metastases with bone-seeking radionuclides].
    De Klerk JM; Zonnenberg BA; Huiskes AW; Han SH; Blijham GH; Van Rijk PP
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2618-22. PubMed ID: 10028362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.
    Rove KO; Crawford ED
    Oncology (Williston Park); 2011 Dec; 25(14):1362-70, 1375-81, 1387. PubMed ID: 22329188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
    Liepe K
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1346-58. PubMed ID: 19943206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
    Pandit-Taskar N; Batraki M; Divgi CR
    J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation for bone metastases.
    Bourgeois DJ; Kraus S; Maaloof BN; Sartor O
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):227-32. PubMed ID: 21734581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.